Hugel shares mildly affected by Bain's stake sale report

Han Jae-beom and Minu Kim 2021. 5. 14. 11:54
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Photo by Hugel Inc.]
Hugel Inc. shares stayed calm, mildly affected by the news that global private equity fund Bain Capital is mulling to cash out of Seoul-listed botox maker by selling its controlling stake.

As of 11:46 am on Friday, Hugel shares traded up 0.1 percent at 203,400 won ($180) after shooting up to as high as 208,000 won in earlier trading.

The U.S. PEF is seeking as much as $2 billion for its 44.4 percent stake in Hugel, Bloomberg reported on Thursday. Bain Capital’s holding in the botox maker is valued at about 1.2 trillion won based on Thursday’s share price, but the sale could fetch about $2 billion when including management premium, the report said.

Bain Capital is working with Bank of America Corp. on the stake sale, which could kick off as soon as the second half of this year, according to Bloomberg, but deliberations are preliminary and the PEF could still decide against a sale.

Hugel, founded in 2001, manufactures botulinum toxin and dermal facial filler used for beauty and cosmetic surgery injections to minimize wrinkles. Bain Capital acquired the controlling stake in Hugel for about $817 million in 2017.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?